TuisTMOS34 • BVMF
add
Thermo Fisher Scientific BDR
Vorige sluiting
R$52,81
Dagwisseling
R$52,81 - R$53,17
Jaarwisseling
R$44,25 - R$71,92
Markkapitalisasie
182,57Â mjd USD
Gemiddelde volume
5,06Â k
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 12,22Â mjd | 7,20% |
Bedryfskoste | 2,46Â mjd | -4,80% |
Netto inkomste | 1,96Â mjd | 7,32% |
Netto winsgrens | 16,08 | 0,12% |
Wins per aandeel | 6,57 | 7,70% |
EBITDA | 3,31Â mjd | 10,32% |
Effektiewe belastingkoers | 7,21% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 10,10Â mjd | 81,42% |
Totale bates | 110,34Â mjd | 13,38% |
Totale aanspreeklikheid | 56,81Â mjd | 19,22% |
Totale ekwiteit | 53,54 mjd | — |
Uitstaande aandele | 371,48 m | — |
Prys om te bespreek | 0,37 | — |
Opbrengs op bates | 6,06% | — |
Opbrengs op kapitaal | 7,11% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,96Â mjd | 7,32% |
Kontant van bedrywe | 3,46Â mjd | 5,08% |
Kontant van beleggings | 891,00Â m | 4Â 355,00% |
Kontant van finansiering | 3,53Â mjd | 196,18% |
Netto kontantverandering | 7,87Â mjd | 1Â 348,89% |
Beskikbare kontantvloei | 2,20Â mjd | -12,06% |
Meer oor
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Gestig
1956
Webwerf
Werknemers
125Â 000